<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.114271</article-id><article-id pub-id-type="publisher-id">ACM-41914</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210400000_77645447.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  血清载脂蛋白A与弥漫大B细胞淋巴瘤患者疗效的相关性研究
  The Study on the Correlation between Serum Apolipoprotein A and the Clinical Efficacy of Patients with Diffuse Large B-Cell Lymphoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>超凤</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>宝怡</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>肖</surname><given-names>敏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>媛</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>林</surname><given-names>素霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>莆田学院药学与医学技术学院，福建 莆田</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>莆田学院附属医院血液风湿科，福建 莆田</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>04</month><year>2021</year></pub-date><volume>11</volume><issue>04</issue><fpage>1253</fpage><lpage>1258</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨弥漫大B细胞淋巴瘤(DLBCL)患者中载脂蛋白A (ApoA)水平的变化及其临床意义。方法：收集67例DLBCL患者的初诊时临床资料，以60例健康体检者为对照，使用R语言进行数据分析。分析数据采用t检验、Mann-Whitney U检验；相关分析采用Spearman相关性分析；采用单因素Cox回归分析和单因素Logistic回归分析ApoA水平与DLBCLH患者治疗效果的相关性。结果：DLBCL患者的ApoA水平(0.95 &#177; 0.25 g/L)低于正常对照组(1.29 &#177; 0.18 g/L)，差异具有统计学意义(P &lt; 0.05)。不同治疗效果的DLBCL患者的ApoA水平差异具有统计学意义(P &lt; 0.05)，两者之间成正相关(R = 0.61, P &lt; 0.05)；单因素Cox回归分析与单因素Logistic回归分析显示ApoA可以用于初步评价DLBCL患者的治疗效果。结论：ApoA是评价DLBCL疗效的辅助指标之一。
   Objective: To investigate the changes and clinical significance of apolipoprotein A (ApoA) level in diffuse large B-cell lymphoma (DLBCL). Methods: 67 patients with DLBCL and 60 healthy normal subjects were collected. The clinical data were analyzed by R programming, measurement data were analyzed with the t-test, Mann-Whitney U test, correction analysis was used by Spearman rank correlation coefficients and regression analysis was through univariate Cox hazard analysis and univariate logistic regression. Results: The level of ApoA in patient with DLBCL (0.95 &#177; 0.25 g/L) was lower than normal control group (1.29 &#177; 0.18 g/L), and difference was statistically significant (P &lt; 0.05). The differences between the clinical efficacy of DLBCL patients and the level of ApoA were statistically significant (P &lt; 0.05), and there was a positive correlation between them (R = 0.61, P &lt; 0.05); the resultes of univariate Cox regression analysis and univariate Logistic regression analysis showed that the level of ApoA can be used to evaluate the clinical efficacy of DLBCL patients. Conclusion: The level of ApoA is one of the auxiliary indicators to evaluate the clinical efficacy of DLBCL.
 
</p></abstract><kwd-group><kwd>弥漫大B细胞淋巴瘤，载脂蛋白A1，血脂水平，疗效, Diffuse Large B-Cell Lymphoma</kwd><kwd> Apolipoprotein A</kwd><kwd> Blood Lipid Level</kwd><kwd> Clinical Efficacy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨弥漫大B细胞淋巴瘤(DLBCL)患者中载脂蛋白A (ApoA)水平的变化及其临床意义。方法：收集67例DLBCL患者的初诊时临床资料，以60例健康体检者为对照，使用R语言进行数据分析。分析数据采用t检验、Mann-Whitney U检验；相关分析采用Spearman相关性分析；采用单因素Cox回归分析和单因素Logistic回归分析ApoA水平与DLBCLH患者治疗效果的相关性。结果：DLBCL患者的ApoA水平(0.95 &#177; 0.25 g/L)低于正常对照组(1.29 &#177; 0.18 g/L)，差异具有统计学意义(P &lt; 0.05)。不同治疗效果的DLBCL患者的ApoA水平差异具有统计学意义(P &lt; 0.05)，两者之间成正相关(R = 0.61, P &lt; 0.05)；单因素Cox回归分析与单因素Logistic回归分析显示ApoA可以用于初步评价DLBCL患者的治疗效果。结论：ApoA是评价DLBCL疗效的辅助指标之一。</p></sec><sec id="s2"><title>关键词</title><p>弥漫大B细胞淋巴瘤，载脂蛋白A1，血脂水平，疗效</p></sec><sec id="s3"><title>The Study on the Correlation between Serum Apolipoprotein A and the Clinical Efficacy of Patients with Diffuse Large B-Cell Lymphoma<sup> </sup></title><p>Chaofeng Zhang<sup>1*</sup>, Baoyi Zhang<sup>2</sup>, Min Xiao<sup>2</sup>, Yuan Lin<sup>1</sup>, Suxia Lin<sup>1#</sup></p><p><sup>1</sup>Department of Hematology and Rheumatology, The Affiliated Hospital of Putian University, Putian Fujian</p><p><sup>2</sup>School of Pharmacy and Medical Technology, Putian University, Putian Fujian</p><p><img src="//html.hanspub.org/file/64-1572122x5_hanspub.png" /></p><p>Received: Mar. 22<sup>nd</sup>, 2021; accepted: Apr. 20<sup>th</sup>, 2021; published: Apr. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/64-1572122x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the changes and clinical significance of apolipoprotein A (ApoA) level in diffuse large B-cell lymphoma (DLBCL). Methods: 67 patients with DLBCL and 60 healthy normal subjects were collected. The clinical data were analyzed by R programming, measurement data were analyzed with the t-test, Mann-Whitney U test, correction analysis was used by Spearman rank correlation coefficients and regression analysis was through univariate Cox hazard analysis and univariate logistic regression. Results: The level of ApoA in patient with DLBCL (0.95 &#177; 0.25 g/L) was lower than normal control group (1.29 &#177; 0.18 g/L), and difference was statistically significant (P &lt; 0.05). The differences between the clinical efficacy of DLBCL patients and the level of ApoA were statistically significant (P &lt; 0.05), and there was a positive correlation between them (R = 0.61, P &lt; 0.05); the resultes of univariate Cox regression analysis and univariate Logistic regression analysis showed that the level of ApoA can be used to evaluate the clinical efficacy of DLBCL patients. Conclusion: The level of ApoA is one of the auxiliary indicators to evaluate the clinical efficacy of DLBCL.</p><p>Keywords:Diffuse Large B-Cell Lymphoma, Apolipoprotein A, Blood Lipid Level, Clinical Efficacy</p><disp-formula id="hanspub.41914-formula40"><graphic xlink:href="//html.hanspub.org/file/64-1572122x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/64-1572122x8_hanspub.png" /> <img src="//html.hanspub.org/file/64-1572122x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>弥漫大B细胞淋巴瘤(DLBCL)是非霍奇金淋巴瘤最常见的一种，具有高度异质性和侵袭性 [<xref ref-type="bibr" rid="hanspub.41914-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref3">3</xref>]。随着R-CHOP方案的应用，大约60%~70%的DLBCL患者可以被治愈，但仍有一部分患者的治疗效果较差，可见不同的DLCBCL分型对疾病的预后存在显著差异 [<xref ref-type="bibr" rid="hanspub.41914-ref3">3</xref>]。根据年龄、Ann Arbor临床分期、结外侵犯、体能状态(PS)和血清乳酸脱氢酶(LDH) 5个因素判定的国际预后指数(IPI)已被广泛用作预测患者生存的预后因素 [<xref ref-type="bibr" rid="hanspub.41914-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref5">5</xref>]。而临床实际工作中常会发现相同IPI评分的患者，治疗效果及预后也存在较大差异，因此有必要寻找出更多的生物学标志物作为IPI的补充。目前有不少预测预后基因和免疫组织化学标记已经被发现，并用于临床，但目前相对高昂的费用限制其临床的广泛使用。故还应选择一些简便易得、较为可靠的指标用于预测DLBCL的预后。有研究表明血脂指标与多种肿瘤的发生和预后密切相关 [<xref ref-type="bibr" rid="hanspub.41914-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref7">7</xref>]，当体内脂质代谢紊乱有可能导致如心血管疾病、神经系统疾病的发生及发展，同时也与肿瘤发生和发展等多个过程密切相关 [<xref ref-type="bibr" rid="hanspub.41914-ref8">8</xref>]。临床上，我们通过检测如下指标：总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDLC)、低密度脂蛋白(LDLC)、载脂蛋白A (ApoA)、载脂蛋白B (ApoB)等来评价血脂水平。故本研究回顾性分析了我院67例DLBCL患者，探讨血脂水平与DLBCL的相关性。</p></sec><sec id="s6"><title>2. 研究对象与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>本研究采用回顾性研究方法，收集2016年1月至2020年12月在我院诊断为DLBCL患者67例(DLBCL)，其中男性35例，女性32例，中位年龄为55 (24.5)岁。所有患者均符合WHO关于DLBCL的诊断标准，全部经病例组织学检查与免疫组化辅助诊断。并排除：1) 合并其他系统恶性肿瘤；2) 合并严重心脑血管疾病；3) 伴有高脂血症并长期口服降血脂药物；4) 严重肝肾功能不全；5) 随访资料不全等。同时在本院体检中心随机抽取同时期选取正常者60例(NOR)，年龄、性别均与DLBCL组相匹配。</p></sec><sec id="s6_2"><title>2.2. 疗效评价</title><p>所纳入的67例患者中，均接受R-CHOP方案至少6个疗程。临床资料随访调查1年，其中疗效评价由2名血液科主治以上医师同时进行，如有异议的情况下由第3名医师进行评估。按2014年Lugano会议修订标准 [<xref ref-type="bibr" rid="hanspub.41914-ref11">11</xref>] 评价疗效，分为完全缓解(CR)，部分缓解(PR)，疾病稳定(SD)和疾病进展(PD)。随访资料截止时间是2020年12月31日。</p></sec><sec id="s6_3"><title>2.3. 检测指标</title><p>如前所述，脂蛋白指标与肿瘤预后存在相关，本研究所纳入的血脂水平指标均来源于本院检验科，主要选取总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDLC)、低密度脂蛋白(LDLC)、载脂蛋白A (ApoA)、载脂蛋白B (ApoB)等指标进行分析。</p></sec><sec id="s6_4"><title>2.4. 统计学分析</title><p>使用Excel记录实验数据，应用R语言(4.0)进行数据分析。对于符合正态分布，方差齐计量资料描述为均数(mean) &#177; 标准误(SE)，差异性分析采用独立样本t检验与单因素方差分析，两两比较使用Tukey检验；对于不符合正态分布或方差不齐的计量资料描述为中位数(四分位距)，差异性分析采用Mann Whitney U检验与Kruskal-Wallis检验，两两比较使用Nemenyi检验。计数资料采用Person X<sup>2</sup>检验和Fisher确切概率法检验，相关性分析采用Sperman秩相关性分析，回归分析则采用单因素Cox回归分析和单因素Logistic回归分析，P &lt; 0.05认为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般情况比较</title><p>比较DLBCL患者治疗前血脂水平指标，与正常对照组血脂水平相比较。2组间的年龄、性别、体重等基本临床特征差异无统计学意义(P &gt; 0.05)，其中DLBCL与NOR的TG、TC、LDLC等比较，差异无统计学意义(P &gt; 0.05)；而HDLC、ApoA、ApoB、LDH比较，差异存在统计学差异(P &lt; 0.05)，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of main clinical data between DLBCL and NO</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >DLBCL</th><th align="center" valign="middle" >NOR</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >55 (24.5)</td><td align="center" valign="middle" >51 (19.25)</td><td align="center" valign="middle" >0.14<sup>a</sup></td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >35/32</td><td align="center" valign="middle" >30/30</td><td align="center" valign="middle" >0.91<sup>b</sup></td></tr><tr><td align="center" valign="middle" >体重</td><td align="center" valign="middle" >76.37 &#177; 4.46</td><td align="center" valign="middle" >76.30 &#177; 5.02</td><td align="center" valign="middle" >0.93</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >1.45 &#177; 0.77</td><td align="center" valign="middle" >1.47 &#177; 0.80</td><td align="center" valign="middle" >0.86</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >4.38 &#177; 1.16</th><th align="center" valign="middle" >4.09 &#177; 0.78</th><th align="center" valign="middle" >0.08<sup>a</sup></th></tr></thead><tr><td align="center" valign="middle" >HDLC</td><td align="center" valign="middle" >1.05 &#177; 0.28</td><td align="center" valign="middle" >1.24 &#177; 0.14</td><td align="center" valign="middle" >&lt;0.05<sup>a</sup></td></tr><tr><td align="center" valign="middle" >LDLC</td><td align="center" valign="middle" >3.12 &#177; 0.95</td><td align="center" valign="middle" >2.95 &#177; 0.31</td><td align="center" valign="middle" >0.63<sup>a</sup></td></tr><tr><td align="center" valign="middle" >ApoA</td><td align="center" valign="middle" >0.95 &#177; 0.25</td><td align="center" valign="middle" >1.29 &#177; 0.18</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >ApoB</td><td align="center" valign="middle" >1.20 &#177; 1.43</td><td align="center" valign="middle" >0.86 &#177; 0.14</td><td align="center" valign="middle" >0.02<sup>a</sup></td></tr><tr><td align="center" valign="middle" >LDH</td><td align="center" valign="middle" >307.71 &#177; 173.87</td><td align="center" valign="middle" >176.55 &#177; 36.86</td><td align="center" valign="middle" >&lt;0.05<sup>a</sup></td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. DLBCL与NOR的主要临床资料比较</p><p>注：a. Mann Whitney U检验；b. Person X<sup>2</sup>检验；其余为t检验，P &lt; 0.05认为差异有统计学意义。</p></sec><sec id="s7_2"><title>3.2. 疗效分析</title><p>所纳入研究中的67例DLBCL患者中，其中CR 24例，PR 14例，SD 19例和PD 10例，对上述有差异的生化指标HDLC、ApoA、ApoB、LDH按疗效分级进行比较，经单因素方差分析可见，4组间ApoA比较，差异具有统计学意义(F = 9.984, P &lt; 0.05)，Tukey检验示，CR与PR、SD、PD之间的差异具有统计学意义(P &lt; 0.05)，而PR、SD、PD之间两两比较差异无统计学意义(P &gt; 0.05)，见表2。然后，我们分析了ApoA值与DLBCL疗效分级的相关性，Spearman秩相关性分析示：ApoA与DLBCL疗效分级成负相关，R = 0.61，P &lt; 0.05。以上提示ApoA值与DLBCL疗效分级有关，疗效越好，ApoA数值越高，相关性分析显示ApoA与DLBCL疗效成正相关。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of related indicators in DLBCL curative effect group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >项目</th><th align="center" valign="middle" >CR</th><th align="center" valign="middle" >PR</th><th align="center" valign="middle" >SD</th><th align="center" valign="middle" >PD</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >N</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >19</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >HDLC</td><td align="center" valign="middle" >1.17 &#177; 0.26</td><td align="center" valign="middle" >0.94 &#177; 0.23</td><td align="center" valign="middle" >1.04 &#177; 0.29</td><td align="center" valign="middle" >0.97 &#177; 0.27</td><td align="center" valign="middle" >0.06</td></tr><tr><td align="center" valign="middle" >ApoA</td><td align="center" valign="middle" >1.12 &#177; 0.24</td><td align="center" valign="middle" >0.93 &#177; 0.14</td><td align="center" valign="middle" >0.87 &#177; 0.24</td><td align="center" valign="middle" >0.74 &#177; 0.13</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >ApoB</td><td align="center" valign="middle" >1.67 &#177; 2.30</td><td align="center" valign="middle" >0.96 &#177; 0.26</td><td align="center" valign="middle" >0.87 &#177; 0.33</td><td align="center" valign="middle" >1.03 &#177; 0.52</td><td align="center" valign="middle" >0.55a</td></tr><tr><td align="center" valign="middle" >LDH</td><td align="center" valign="middle" >274.94 &#177; 94.38</td><td align="center" valign="middle" >336.22 &#177; 192.45</td><td align="center" valign="middle" >341.59 &#177; 245.20</td><td align="center" valign="middle" >282.02 &#177; 133.81</td><td align="center" valign="middle" >0.94a</td></tr></tbody></table></table-wrap><p>表2. DLBCL疗效分组中相关指标比较</p><p>注：a. Kruskal-Wallis检验，其余使用单因素方差分析，P &lt; 0.05认为差异有统计学意义。</p></sec><sec id="s7_3"><title>3.3. 单因素回归分析</title><p>单因素方差分析显示ApoA与DLBCL的疗效关系较大，为进一步分析ApoA是否是评价DLBCL疗效的辅助指标，我们对ApoA与DLBCL的疗效进行单因素Cox回归分析，结果示ApoA水平与DLBCL疗效密切相关(P &lt; 0.05)。进一步，将CR + PR定义为治疗有效，SD+PD定义为治疗无效；以ApoA值1 g/L为界，分为高ApoA组(&gt; 1 g/L)和低ApoA组(≤ 1 g/L)，t检验结果示ApoA在治疗有效与治疗无效中差异具有统计学意义(治疗有效vs.治疗无效：0.82 &#177; 0.23 vs. 1.05 &#177; 0.22, t = −4.17, P &lt; 0.05)，随后进行单因素Logistic回归分析，结果表明ApoA水平可以预测DLBCL疗效(P &lt; 0.05)，见表3。以上证据提示ApoA具有预测DLBCL疗效的重要价值。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Regression analysis of ApoA on the prognosis of DLBC</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >项目</th><th align="center" valign="middle"  colspan="2"  >单因素Cox回归分析</th><th align="center" valign="middle"  colspan="2"  >单因素Logistic回归分析</th></tr></thead><tr><td align="center" valign="middle" >z value</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >z value</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >APOA</td><td align="center" valign="middle" >4.562</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >3.720</td><td align="center" valign="middle" >0.0006</td></tr></tbody></table></table-wrap><p>表3. ApoA对DLBCL预后的回归分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>血脂水平与肿瘤的发生和发展相关 [<xref ref-type="bibr" rid="hanspub.41914-ref8">8</xref>]。有研究表明不同肿瘤类型，血脂水平以及血脂代谢中的不同指标都对肿瘤的发生发展、预后及疗效均有不同的临床价值。ApoA是HDLC的主要载脂蛋白，主要在肝脏和小肠合成。参与胆固醇逆向运输及炎症和免疫应答调节，并具有抗氧化和抗炎作用。现有研究表明：除了抗动脉粥样硬化作用等心脏保护功能以外 [<xref ref-type="bibr" rid="hanspub.41914-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref13">13</xref>]，ApoA与肿瘤发生发展存在一定关系，如卵巢癌、膀胱癌及结肠癌中均出现表达异常 [<xref ref-type="bibr" rid="hanspub.41914-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref15">15</xref>]，ApoA还广泛参与了多种肿瘤的调节 [<xref ref-type="bibr" rid="hanspub.41914-ref14">14</xref>]。在血液系统肿瘤中，ApoA也发挥重要的作用。沈静等学者 [<xref ref-type="bibr" rid="hanspub.41914-ref16">16</xref>] 发现低浓度的ApoA是多发性骨髓瘤的独立危险因素。在儿童急性淋巴细胞白血病(ALL)患者中，发现ApoA水平明显降低，在ALL治疗缓解的患者中，ApoA水平升高 [<xref ref-type="bibr" rid="hanspub.41914-ref17">17</xref>]。但目前ApoA在恶性淋巴瘤中的水平尚未见报道。</p><p>在DLBCL的预后与疗效评价研究上，随着分子病理和基因靶点的研究进展 [<xref ref-type="bibr" rid="hanspub.41914-ref4">4</xref>]，IPI也逐渐发展出了年龄调整的IPI、改良的IPI等，这无疑是对DLBCL预后评价做了极大的补充。ApoA是临床生化全套常用脂蛋白指标，已经被证明在多种肿瘤中水平下降 [<xref ref-type="bibr" rid="hanspub.41914-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref16">16</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref17">17</xref>]，未发现ApoA在DLBCL的表达水平，本研究首先比较了正常人群与DLBCL患者的ApoA等脂蛋白指标，发现相对于正常人群，DLBCL的ApoA明显降低(P &lt; 0.05)。进一步以疗效对DLBCL进行分型，发现在治疗无效中ApoA的水平更低(P &lt; 0.05)，继而，进行单因素Cox回归分析和单因素Logistic回归分析，可见ApoA可以用于评价DLBCL疗效。</p><p>ApoA用于DLBCL疗效的评价研究，这在国内外尚属首次。有研究 [<xref ref-type="bibr" rid="hanspub.41914-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.41914-ref14">14</xref>] 证明了ApoA可以发挥抑制肿瘤细胞的作用。可能的作用机制与ApoA抗氧化、免疫调节、促进脂代谢、抑制新生血管等有关，其中更为关键的作用机制尚未完全阐明。宏观层面上，通过单因素Cox回归分析，我们可以发现ApoA的水平与DLBCL的治疗效果正相关，提示ApoA的低水平与DLBCL的PR、PD、SD有关，进一步提示ApoA与肿瘤负荷有关 [<xref ref-type="bibr" rid="hanspub.41914-ref16">16</xref>]。同时因ApoA检测便捷，检测样本不受饮食及其他因素影响，可以作为评价DLBCL疗效的辅助指标。</p><p>由于研究条件有限，我们纳入研究的患者数量略少，不同患者间的差异也较大，为进一步明确ApoA在DLBCL疗效评价中的价值，有待于进一步开展多中心、大样本研究证明。</p></sec><sec id="s9"><title>基金项目</title><p>福建省卫生计生青年科研课题(2017-2-79)；福建省教育厅中青年教师教育科研立项(JAT190562)；莆田市科技计划项目(2018S3F006，2019S3F002)；莆田学院校级教育教学改革研究立项项目的通知(JG202048)。</p></sec><sec id="s10"><title>文章引用</title><p>张超凤,张宝怡,肖 敏,林 媛,林素霞. 血清载脂蛋白A与弥漫大B细胞淋巴瘤患者疗效的相关性研究The Study on the Correlation between Serum Apolipoprotein A and the Clinical Efficacy of Patients with Diffuse Large B-Cell Lymphoma[J]. 临床医学进展, 2021, 11(04): 1253-1258. https://doi.org/10.12677/ACM.2021.114271</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41914-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Li, S., Young, K.H. and Medeiros, L.J. (2018) Diffuse Large B-Cell Lymphoma. Pathology, 50, 74-87.  
&lt;br&gt;https://doi.org/10.1016/j.pathol.2017.09.006</mixed-citation></ref><ref id="hanspub.41914-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kubuschok, B., Held, G. and Pfreundschuh, M. (2015) Management of Diffuse Large B-Cell Lymphoma (DLBCL). Cancer Treatment and Research, 165, 271-288. &lt;br&gt;https://doi.org/10.1007/978-3-319-13150-4_11</mixed-citation></ref><ref id="hanspub.41914-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sarkozy, C. and Sehn, L.H. (2018) Management of Relapsed/Refractory DLBCL. Best Practice &amp; Research: Clinical Haematology, 31, 209-216. &lt;br&gt;https://doi.org/10.1016/j.beha.2018.07.014</mixed-citation></ref><ref id="hanspub.41914-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S.N. and Bai, O. (2016) The Advances of Clinical and Molecular Prognostic Factors of Diffuse Large B-Cell Lymphoma. Chinese Journal of Hematology, 37, 538-541.</mixed-citation></ref><ref id="hanspub.41914-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Y. and Barta, S.K. (2019) Diffuse Large B-Cell Lymphoma: 2019 Update on Diagnosis, Risk Stratification, and Treatment. American Journal of Hematology, 94, 604-616. &lt;br&gt;https://doi.org/10.1002/ajh.25460</mixed-citation></ref><ref id="hanspub.41914-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dong, Y., Wang, H., Shan, D., et al. (2020) Correlation between Pretreatment Serum Apolipoprotein Level and Prognosis of Small Cell Lung Cancer Patients. Chinese Journal of Lung Cancer, 23, 845-851.</mixed-citation></ref><ref id="hanspub.41914-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Dong, Y., Wang, H., Shan, D., et al. (2020) Research Progress on the Relationship between Blood Lipids and Lung Cancer Risk and Prognosis. Chinese Journal of Lung Cancer, 23, 824-829.</mixed-citation></ref><ref id="hanspub.41914-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Huang, C. and Freter, C. (2015) Lipid Metabolism, Apoptosis and Cancer Therapy. IJMS, 16, 924-949.  
&lt;br&gt;https://doi.org/10.3390/ijms16010924</mixed-citation></ref><ref id="hanspub.41914-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Liu, Z.-L., Wu, Y.-T., et al. (2018) Status of Lipid and Lipoprotein in Female Breast Cancer Patients at Initial Diagnosis and during Chemotherapy. Lipids in Health and Disease, 17, 91. &lt;br&gt;https://doi.org/10.1186/s12944-018-0745-1</mixed-citation></ref><ref id="hanspub.41914-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Allott, E.H., Howard, L.E., Cooperberg, M.R., et al. (2014) Serum Lipid Profile and Risk of Prostate Cancer Recurrence: Results from the Search Database. Cancer Epidemiology, Biomarkers &amp; Prevention, 23, 2349-2356.  
&lt;br&gt;https://doi.org/10.1158/1055-9965.EPI-14-0458</mixed-citation></ref><ref id="hanspub.41914-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Cheson, B.D., Fisher, R.I., Barrington, S.F., et al. (2014) Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. Journal of Clinical Oncology, 32, 3059-3068. &lt;br&gt;https://doi.org/10.1200/JCO.2013.54.8800</mixed-citation></ref><ref id="hanspub.41914-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Cochran, B.J., Ong, K.-L., Manandhar, B., et al. (2021) APOA1: A Protein with Multiple Therapeutic Functions. Current Atherosclerosis Reports, 23, 11. &lt;br&gt;https://doi.org/10.1007/s11883-021-00906-7</mixed-citation></ref><ref id="hanspub.41914-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zamanian-Daryoush, M., Lindner, D., Tallant, T.C., et al. (2013) The Cardioprotective Protein Apolipoprotein A1 Promotes Potent Anti-Tumorigenic Effects. Journal of Biological Chemistry, 288, 21237-21252.  
&lt;br&gt;https://doi.org/10.1074/jbc.M113.468967</mixed-citation></ref><ref id="hanspub.41914-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y. and Yang, X. (2018) Prognostic Significance of Pretreatment Apolipoprotein A-I as a Noninvasive Biomarker in Cancer Survivors: A Meta-Analysis. Disease Markers, 2018, Article ID: 1034037.  
&lt;br&gt;https://doi.org/10.1155/2018/1034037</mixed-citation></ref><ref id="hanspub.41914-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">van Duijnhoven, F.J.B., Bueno-de-Mesquita, H.B., Calligaro, M., et al. (2011) Blood Lipid and Lipoprotein Concentrations and Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. Gut, 60, 1094-1102.  
&lt;br&gt;https://doi.org/10.1136/gut.2010.225011</mixed-citation></ref><ref id="hanspub.41914-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Shen, J., Yang, R.H., Zhang, Y.C., et al. (2020) The Influence of Apolipoprotein A1 on the Prognosis of Multiple Myeloma. Chinese Journal of Hematology, 41, 675-679.</mixed-citation></ref><ref id="hanspub.41914-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Halton, J.M., Nazir, D.J., Mcqueen, M.J., et al. (1998) Blood Lipid Profiles in Children with Acute Lymphoblastic Leukemia. Cancer, 83, 379-384.  
&lt;br&gt;https://doi.org/10.1002/(SICI)1097-0142(19980715)83:2&lt;379::AID-CNCR24&gt;3.0.CO;2-P</mixed-citation></ref></ref-list></back></article>